193 related articles for article (PubMed ID: 35371997)
1. Multi-Faceted Effects of ST6Gal1 Expression on Precursor B-Lineage Acute Lymphoblastic Leukemia.
Zhang M; Qi T; Yang L; Kolarich D; Heisterkamp N
Front Oncol; 2022; 12():828041. PubMed ID: 35371997
[TBL] [Abstract][Full Text] [Related]
2. Galectin-1 and Galectin-3 in B-Cell Precursor Acute Lymphoblastic Leukemia.
Fei F; Zhang M; Tarighat SS; Joo EJ; Yang L; Heisterkamp N
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430839
[TBL] [Abstract][Full Text] [Related]
3. Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia.
Tarighat SS; Fei F; Joo EJ; Abdel-Azim H; Yang L; Geng H; Bum-Erdene K; Grice ID; von Itzstein M; Blanchard H; Heisterkamp N
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830047
[TBL] [Abstract][Full Text] [Related]
4. The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk modulates sialylation of EGFR via PI3K/Akt pathway in T-cell acute lymphoblastic leukemia.
Liu Q; Ma H; Sun X; Liu B; Xiao Y; Pan S; Zhou H; Dong W; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):199. PubMed ID: 31096997
[TBL] [Abstract][Full Text] [Related]
5. Analysis of acute lymphoblastic leukemia drug sensitivity by changes in impedance via stromal cell adherence.
Luong A; Cerignoli F; Abassi Y; Heisterkamp N; Abdel-Azim H
PLoS One; 2021; 16(9):e0258140. PubMed ID: 34591931
[TBL] [Abstract][Full Text] [Related]
6. Blood-Borne ST6GAL1 Regulates Immunoglobulin Production in B Cells.
Irons EE; Punch PR; Lau JTY
Front Immunol; 2020; 11():617. PubMed ID: 32391003
[TBL] [Abstract][Full Text] [Related]
7. Chinese hamster ovary (CHO) host cell engineering to increase sialylation of recombinant therapeutic proteins by modulating sialyltransferase expression.
Lin N; Mascarenhas J; Sealover NR; George HJ; Brooks J; Kayser KJ; Gau B; Yasa I; Azadi P; Archer-Hartmann S
Biotechnol Prog; 2015; 31(2):334-46. PubMed ID: 25641927
[TBL] [Abstract][Full Text] [Related]
8. Drug-tolerant persister B-cell precursor acute lymphoblastic leukemia cells.
Zhang M; Yang L; Chen D; Heisterkamp N
bioRxiv; 2023 Mar; ():. PubMed ID: 36909619
[TBL] [Abstract][Full Text] [Related]
9. Extracellular sialyltransferase st6gal1 in breast tumor cell growth and invasiveness.
Hait NC; Maiti A; Wu R; Andersen VL; Hsu CC; Wu Y; Chapla DG; Takabe K; Rusiniak ME; Bshara W; Zhang J; Moremen KW; Lau JTY
Cancer Gene Ther; 2022 Nov; 29(11):1662-1675. PubMed ID: 35676533
[TBL] [Abstract][Full Text] [Related]
10. Replication timing alterations in leukemia affect clinically relevant chromosome domains.
Rivera-Mulia JC; Sasaki T; Trevilla-Garcia C; Nakamichi N; Knapp DJHF; Hammond CA; Chang BH; Tyner JW; Devidas M; Zimmerman J; Klein KN; Somasundaram V; Druker BJ; Gruber TA; Koren A; Eaves CJ; Gilbert DM
Blood Adv; 2019 Nov; 3(21):3201-3213. PubMed ID: 31698451
[TBL] [Abstract][Full Text] [Related]
11. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia.
Cayuela JM; Baruchel A; Orange C; Madani A; Auclerc MF; Daniel MT; Schaison G; Sigaux F
Blood; 1996 Jul; 88(1):302-8. PubMed ID: 8704188
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells.
Iwasa M; Miura Y; Fujishiro A; Fujii S; Sugino N; Yoshioka S; Yokota A; Hishita T; Hirai H; Andoh A; Ichinohe T; Maekawa T
Int J Hematol; 2017 May; 105(5):587-597. PubMed ID: 28044259
[TBL] [Abstract][Full Text] [Related]
13. Loss of core fucosylation in both ST6GAL1 and its substrate enhances glycoprotein sialylation in mice.
Huang G; Li Z; Li Y; Liu G; Sun S; Gu J; Kameyama A; Li W; Dong W
Biochem J; 2020 Mar; 477(6):1179-1201. PubMed ID: 32141499
[TBL] [Abstract][Full Text] [Related]
14. ST6GAL1: A key player in cancer.
Garnham R; Scott E; Livermore KE; Munkley J
Oncol Lett; 2019 Aug; 18(2):983-989. PubMed ID: 31423157
[TBL] [Abstract][Full Text] [Related]
15. Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008.
Paz H; Joo EJ; Chou CH; Fei F; Mayo KH; Abdel-Azim H; Ghazarian H; Groffen J; Heisterkamp N
J Exp Clin Cancer Res; 2018 Mar; 37(1):67. PubMed ID: 29580262
[TBL] [Abstract][Full Text] [Related]
16. β-Galactoside α2,6-sialyltranferase 1 promotes transforming growth factor-β-mediated epithelial-mesenchymal transition.
Lu J; Isaji T; Im S; Fukuda T; Hashii N; Takakura D; Kawasaki N; Gu J
J Biol Chem; 2014 Dec; 289(50):34627-41. PubMed ID: 25344606
[TBL] [Abstract][Full Text] [Related]
17. Viable bone marrow stromal cells are required for the in vitro survival of B-cell precursor acute lymphoblastic leukemic cells.
Ashley DM; Bol SJ; Kannourakis G
Leuk Res; 1995 Feb; 19(2):113-20. PubMed ID: 7869739
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow T helper cells with a Th1 phenotype induce activation and proliferation of leukemic cells in precursor B acute lymphoblastic leukemia patients.
Traxel S; Schadt L; Eyer T; Mordasini V; Gysin C; Munthe LA; Niggli F; Nadal D; Bürgler S
Oncogene; 2019 Mar; 38(13):2420-2431. PubMed ID: 30532071
[TBL] [Abstract][Full Text] [Related]
19. [Effects of bone marrow stromal cells on the chemotherapeutic sensitivity of acute lymphoblastic leukemia cells].
Wang Y; Han ZX; Zhang JC
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):885-890. PubMed ID: 29262503
[No Abstract] [Full Text] [Related]
20. Expression of p53 N-terminal isoforms in B-cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles.
Oh L; Hainaut P; Blanchet S; Ariffin H
BMC Cancer; 2020 Feb; 20(1):110. PubMed ID: 32041553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
